# A Study of Remternetug (LY3372993) in Healthy Chinese Participants

> **NCT07346495** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 24 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** LY3372993
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07346495
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-01-31
- **Primary completion:** 2026-08
- **Final completion:** 2027-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07346495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07346495, "A Study of Remternetug (LY3372993) in Healthy Chinese Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07346495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*